AAA
ANAB icon

Affinity Asset Advisors’s AnaptysBio ANAB Stock Holding History

Affinity Asset Advisors’s Portfolio ANAB Stock Details ANAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-200,000
Closed -$6.7M – 86
2024
Q3 		$6.7M Buy
+200,000
New +$6.83M 0.91% 36

Other funds holding ANAB

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Affinity Asset Advisors's ANAB Position: Q1 2026 in Review

Affinity Asset Advisors increased its AnaptysBio (ANAB) stake by 111% in Q1 2026, buying an estimated $26.6M and bringing the position to 940,000 shares worth $52.1M. The position accounts for 2.69% of the portfolio, ranked #10.

Affinity Asset Advisors first reported a position in ANAB in Q4 2025 and has held it in 2 quarters since. 207 funds tracked by Wall St. Rank hold ANAB as of Q1 2026.

  • Affinity Asset Advisors held 940,000 shares of AnaptysBio worth $52.1M as of Q1 2026.
  • Affinity Asset Advisors bought 495,308 AnaptysBio shares in Q1 2026, an estimated $26.6M.
  • AnaptysBio made up 2.69% of Affinity Asset Advisors's portfolio in Q1 2026, its #10 holding.
  • Affinity Asset Advisors first reported a position in AnaptysBio in Q4 2025 and has held it in 2 quarters since.
  • 207 funds tracked by Wall St. Rank held AnaptysBio as of Q1 2026.

Based on Affinity Asset Advisors's 13F filing for Q1 2026, filed 14 May 2026.